Trial Profile
First‑line gefitinib treatment in elderly patients (aged ≥75 years) with non‑small cell lung cancer harboring EGFR mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2016
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Feb 2016 New trial record